Here is how to take a cautious approach to testosterone therapy. Although this new information is somewhat reassuring, men and their doctors should still weigh these issues before committing to long term testosterone therapy. Doctors also watch out for high red blood cell counts, which could increase the risk of clotting. Men can often feel a big difference when they stop therapy because their body's testosterone production has not yet recovered. On treatment, the body stops making testosterone.
This study was done according to Centre for Reviews and Dissemination guidance for undertaking reviews in health care and the Cochrane Handbook for Systematic Reviews of Interventions.29, 30 Results were reported according to the PRISMA IPD checklist.31 Methods were pre-specified in a research protocol. Studies in which participants received non-testosterone drugs to increase androgen levels (eg, human chorionic gonadotropin, selective oestrogen receptor modulators) or concomitant interventions were not included. (2) The intervention of interest was treatment with any testosterone formulation, dose frequency, and route of administration, for a minimum duration of 3 months. Testosterone exerts diverse effects on cardiovascular physiology. Testosterone treatment is the standard of care for reversing the consequences of hypogonadism.
We report results of the most extensive individual participant dataset (IPD) of testosterone trials available and aimed to analyse subtypes of all cardiovascular events observed during treatment, and analyse the effect of incorporating data from trials not providing IPD. Men with hypogonadism should be counselled that there is no current evidence that testosterone treatment increases cardiovascular risk in the short to medium term. We aimed to provide the most extensive individual participant dataset (IPD) of testosterone trials available, to analyse subtypes of all cardiovascular events observed during treatment, and to investigate the effect of incorporating data from trials that did not provide IPD. The benefit-risk balance of these medicines has been reviewed following recent published evidence pointing to an increased risk of cardiovascular events, particularly myocardial infarction, in men treated with testosterone.
However, the current results provide some reassurance about the short-term to medium-term safety of testosterone to treat male hypogonadism. Testosterone treatment did not increase cardiovascular event risk in the short term to medium term. Results of this meta-analysis have potentially important implications for the management of men with hypogonadism. We did not observe any significant association between baseline testosterone and risks of any adverse outcome. However, only five cases of deep vein thromboses were recorded during testosterone treatment, compared with seven in the placebo group.
Most testosterone levels tests involve a blood draw in a medical setting. Your health care provider can measure your testosterone levels by ordering one of three tests. A testosterone levels test measures the amount of the hormone testosterone in a sample of your blood. Gagliano-Jucá, T., Basaria, S. Testosterone replacement therapy and cardiovascular risk.

Gender: Female

Social links